Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

Documenti analoghi

• Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies from 2015 – 2019
  di: Douglas, Michael P., et al.
  Pubblicazione: (2020)
• Health Technology Assessment and Private Payers' Coverage of Personalized Medicine
  di: Trosman, Julia R., et al.
  Pubblicazione: (2011)
• Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative
  di: Trosman, Julia R., et al.
  Pubblicazione: (2017)
• Perspectives of U.S. Private Payers on Insurance Coverage for Pediatric and Prenatal Exome Sequencing – Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS)
  di: Trosman, Julia R., et al.
  Pubblicazione: (2019)
• Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In
  di: Trosman, Julia R., et al.
  Pubblicazione: (2015)